Regulation of calcification by bisphosphonates

Etidronate, an analogue of first generation of bisphosphonates, has inhibitory actions on mineralization and hydroxyapatite crystal formation, which is therefore used as a drug to treat ectopic ossification in cases with total hip arthroplasty and spinal cord injury. The effect of bisphosphonates to...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical calcium Vol. 14; no. 6; p. 60
Main Authors:	Ono, Katsuhiro, Wada, Seiki
Format:	Journal Article
Language:	Japanese
Published:	Japan 01-06-2004
Subjects:	Animals Arteriosclerosis - prevention & control Arthroplasty, Replacement, Hip - adverse effects Calcinosis - prevention & control Crystallization Diphosphonates - pharmacology Diphosphonates - therapeutic use Drug Design Durapatite - metabolism Humans Ossification, Heterotopic - drug therapy Ossification, Heterotopic - etiology Ossification, Heterotopic - prevention & control Spinal Cord Injuries - complications
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Etidronate, an analogue of first generation of bisphosphonates, has inhibitory actions on mineralization and hydroxyapatite crystal formation, which is therefore used as a drug to treat ectopic ossification in cases with total hip arthroplasty and spinal cord injury. The effect of bisphosphonates to prevent calcification could be associated with the physical property to attach tightly to hydroxyapatite crystals in bone matrix. A recent investigation suggested that bisphosphonates might prevent arterial calcification through a mechanism associated with the enhanced production of parathyroid hormone-related peptide from vascular smooth muscle cells. A derivative of bisphosphonates to inhibit vascular calcification in atherosclerosis is expected and should be developed in the near future.
ISSN:	0917-5857